More than 100 scientific abstracts on six Bristol-Myers
Squibb Company (NYSE:BMY) oncology compounds will be presented at
the 44th Annual Meeting of the American Society of Clinical Oncology
(ASCO) in Chicago from May 30- June 2.
Data will be presented on ERBITUX®
(cetuximab), SPRYCEL®
(dasatinib), IXEMPRA®
(ixabepilone) and investigational compounds ipilimumab, brivanib
and CT-322. Studies focus on a broad spectrum of cancer types, including
colorectal, head and neck, leukemia, lung, breast, melanoma and prostate.
“As cancer therapy evolves, so does
Bristol-Myers Squibb’s innovation in finding
new ways to address significant unmet medical needs,”
said Elliott Sigal, M.D., Ph.D., executive vice president, chief
scientific officer and president, Research and Development,
Bristol-Myers Squibb. “The data being
presented at this year’s ASCO annual meeting
reflect the broader potential of our medicines as we explore new ways to
help fight cancer. Our robust oncology pipeline holds the promise and
potential of delivering additional treatment options for physicians and
patients.”
Bristol-Myers Squibb, and its partners ImClone Systems, Inc. and Merck
KGaA, plan to present new data on ERBITUX, including two studies that
will be featured in ASCO plenary sessions and an ASCO press briefing on
Sunday, June 1. The companies are investigating the potential of ERBITUX
in non-small cell lung cancer and data from a large, completed phase III
trial in this tumor type will be presented for the first time at ASCO.
Also to be presented are retrospective analyses assessing the link
between patients’ KRAS gene status of the
individual’s tumor and the treatment effect
with ERBITUX. Both trials have been planned and conducted by Merck KGaA,
Darmstadt, Germany.
Data on SPRYCEL will be featured in two studies of patients with chronic
myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia
(Ph+ALL) with up to two years of follow-up. For the first time, Phase 2
data will be presented on the potential of SPRYCEL in prostate cancer.
The company is actively investigating the potential of SPRYCEL in other
solid tumor types, including glioblastoma, breast cancer and colorectal
cancer.
IXEMPRA will be highlighted in abstracts evaluating combination regimens
with other chemotherapies or targeted agents, as well as in additional
tumor types.
Bristol-Myers Squibb and its partner Medarex will present data on the
investigational immunotherapy ipilimumab. New Phase 2 ipilimumab data
will evaluate the medicine’s potential in
patients with metastatic melanoma.
New data on Bristol-Myers Squibb compounds, brivanib and CT-322, will
also be presented at ASCO. CT-322 was discovered by Adnexus
Therapeutics, which was acquired by Bristol-Myers Squibb in October
2007. CT-322 is being evaluated for use in the treatment of
glioblastoma, a type of brain cancer, and will be featured in an oral
presentation at ASCO. Brivanib is being investigated for use in
colorectal and other cancers.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to extend and enhance human life.
Full prescribing information for ERBITUX, SPRYCEL and IXEMPRA is
available at http://www.bms.com/.
